Medexus Pharmaceuticals (TSE:MDP) Upgraded to “Strong-Buy” at Raymond James

Raymond James upgraded shares of Medexus Pharmaceuticals (TSE:MDPFree Report) from an outperform rating to a strong-buy rating in a report issued on Wednesday morning,BayStreet.CA reports. The firm currently has C$4.00 target price on the stock.

A number of other brokerages also recently issued reports on MDP. Alliance Global Partners upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, December 23rd. Leede Financial set a C$8.25 price target on shares of Medexus Pharmaceuticals and gave the stock a “speculative buy” rating in a research report on Monday, September 30th. Two research analysts have rated the stock with a buy rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat, Medexus Pharmaceuticals currently has a consensus rating of “Strong Buy” and an average price target of C$5.25.

View Our Latest Stock Analysis on Medexus Pharmaceuticals

Medexus Pharmaceuticals Stock Up 4.0 %

Shares of Medexus Pharmaceuticals stock opened at C$3.60 on Wednesday. The stock has a market cap of C$88.31 million, a price-to-earnings ratio of 72.00 and a beta of 1.96. Medexus Pharmaceuticals has a twelve month low of C$1.47 and a twelve month high of C$3.60. The company’s fifty day moving average is C$2.72 and its 200 day moving average is C$2.50.

About Medexus Pharmaceuticals

(Get Free Report)

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.

Featured Articles

Analyst Recommendations for Medexus Pharmaceuticals (TSE:MDP)

Receive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.